Best Onclive On Air Podcasts (2025)

1
S14 Ep62: VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD 8:46

Play Pause

2h ago8:46

8:46

In today’s episode, we had the pleasure of speaking with Catherine Shu, MD, about the use of tepotinib (Tepmetko) in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations. Dr Shu is the Price Family Associate Professor of Medicine and the clinical director of the Thoracic Medical Oncology Service at the Columbia Universi…

1
S14 Ep61: PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD 33:06

1d ago33:06

33:06

In this episode, Gregory J. Tiesi, MD, FACS, FSSO, hosted a discussion about innovations in regional cancer therapies. Dr Tiesi is the medical director of Hepatobiliary Surgery at the Hackensack Meridian Jersey Shore University Medical Center in Toms River and Brick, New Jersey. He was joined by: Anthony Scholer, MD, FACS, FSSO, a surgical oncologi…

1
S14 Ep60: ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD 11:14

2d ago11:14

11:14

In today’s episode, we had the pleasure of speaking with Sarah Rutherford, MD, about the evolving role of minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing for lymphoma treatment decision-making. Dr Rutherford is an associate professor of clinical medicine in the Division of Hematology/Oncology at Weill Cornell Medicine in Ne…

1
S14 Ep59: Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS 4:16

3d ago4:16

4:16

In today’s episode, we had the pleasure of speaking with Shubham Pant, MD, MBBS, about the first-line treatment of patients with metastatic pancreatic cancer. Dr Pant is a professor in the Department of Gastrointestinal (GI) Medical Oncology of the Division of Cancer Medicine, director of Clinical Research, and a professor in the Department of Inve…

1
S14 Ep58: Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD 13:49

4d ago13:49

13:49

In today’s episode, we had the pleasure of speaking with Jacob Sands, MD, and Shailee Shah, MD, about considerations for diagnosing and managing Lambert-Eaton myasthenic syndrome (LEMS), particularly in the context of small cell lung cancer (SCLC). Dr Sands is associate chief of the Lowe Center for Thoracic Oncology and the Oncology Medical Directo…

1
S14 Ep57: Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD 6:12

7d ago6:12

6:12

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. I…

1
S14 Ep56: Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS 5:58

8d ago5:58

5:58

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. I…

1
S14 Ep55: Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD 20:18

10d ago20:18

20:18

In today’s episode, we had the pleasure of speaking with Daniel Spratt, MD, chair and professor in the Department of Radiation Oncology at Case Western Reserve University School of Medicine and a member of the Case Comprehensive Cancer Center in Cleveland, Ohio. Dr Spratt discussed key updates to the National Comprehensive Cancer Network (NCCN) Gui…

1
S14 Ep54: Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD 16:58

11d ago16:58

16:58

In today’s episode,filmed live at the 43rd Annual CFS Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with breast cancer experts Kamel Abou Hussein, MD, and Victoria Rizk, MD, about the rapidly evolving therapeutic landscape in breast cancer. Dr Levy is the clinical director of medical…

1
S14 Ep53: Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD 7:43

11d ago7:43

7:43

In today’s episode, we had the pleasure of speaking with Marc S. Raab, MD, about the post-induction outcomes and updated minimal residual disease (MRD) analyses from the phase 2 MajesTEC-5 study (NCT05695508), which is evaluating teclistamab-cqyv (Tecvayli)–based induction regimens in patients with newly diagnosed multiple myeloma. Dr Raab is a pro…

1
S14 Ep52: FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD 20:37

14d ago20:37

20:37

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. I…

1
S14 Ep51: Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD 14:57

16d ago14:57

14:57

In today’s episode, we had the pleasure of speaking with Justin Taylor, MD, an associate professor in the Division of Hematology at the University of Miami Miller School of Medicine, about the growing role of artificial intelligence in cancer information–seeking and what this means for clinicians caring for patients with hematologic malignancies. D…

1
S14 Ep50: Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS 9:13

16d ago9:13

9:13

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, an…

1
S14 Ep49: Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc 27:53

20d ago27:53

27:53

In today’s episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted an in-depth discussion with Jonathan W. Lee, MD, MSc, on the evolving therapeutic landscape for EGFR-mutant and HER2-positive non–small cell lung cancer (NSCLC). Dr Levy is the clinical director of medical oncology a…

1
S14 Ep48: PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO 26:38

23d ago26:38

26:38

In today’s episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with genitourinary (GU) cancer expert Scott T. Tagawa, MD, MS, FACP, FASCO, about the rapidly evolving treatment paradigms for prostate and kidney cancer. Dr Levy is the clinical director…

1
S14 Ep47: Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, 19:10

22d ago19:10

19:10

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber…

1
S14 Ep46: Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS 4:43

23d ago4:43

4:43

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, an…

1
S14 Ep45: Urothelial ESMO 2025 Updates 13:11

24d ago13:11

13:11

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University…

1
S14 Ep44: Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO 9:39

28d ago9:39

9:39

In today’s episode, we had the pleasure of speaking with Kevin Kalinsky, MD, MS, FASCO, about the evolving treatment paradigm for hormone receptor (HR)–positive breast cancer post-CDK4/6 inhibition, as well as the need for more advanced therapies to improve patient outcomes in this setting. Dr Kalinsky is a professor and director in the Division of…

1
S14 Ep43: ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD 11:21

28d ago11:21

11:21

In today’s episode, we had the pleasure of speaking with Stephen Liu, MD, about the potential role for zidesamtinib (NVL-520) for the treatment of patients with advanced non–small cell lung cancer (NSCLC) harboring ROS1 rearrangements. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncolog…

1
S14 Ep42: Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC 4:53

28d ago4:53

4:53

Dr Mian discussed why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristicBy OncLive® On Air

1
S14 Ep41: Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO 19:00

29d ago19:00

19:00

In today’s episode, we had the pleasure of speaking with Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO, about the potential clinical implications of the phase 3 IRAKLIA (NCT05405166) and phase 2 IZALCO (NCT05704049) studies, which investigated the use of isatuximab-irfc (Sarclisa) administered via an on-body deli…

1
S14 Ep40: Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS 5:12

1M ago5:12

5:12

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, an…

1
S14 Ep39: Oncology Experts Dive Into Top Data From ESMO 2025 17:53

1M ago17:53

17:53

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.By OncLive® On Air

1
S14 Ep38: Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS 12:20

1M ago12:20

12:20

In today’s episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about the use of androgen deprivation therapy (ADT) in prostate cancer management. Dr Shore is medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina. In our exclusive interview, Dr Shore discussed guidelines for incorporating ADT into …

1
S14 Ep37: Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD 29:09

1M ago29:09

29:09

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jer…

1
S14 Ep36: Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD 26:42

1M ago26:42

26:42

Dr Mehta discussed practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025, the clinical utility of enfortumab vedotin plus pembrolizumab for select patients with advanced or metastatic urothelial cancer, and differing treatment approaches for patients with lymph node–only vs distant metastases.…

1
S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD 15:12

1M ago15:12

15:12

In today’s episode, we had the pleasure of speaking with Armeen Mahvash, MD, about the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma. Dr Mahvash is a professor in the Department of Interventional Radiology in the Division of Diagnostic Imaging at The University of Texas …

1
S14 Ep34: FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS 12:11

1M ago12:11

12:11

In today’s episode, we had the pleasure of speaking with Vishal A. Patel, MD, FAAD, FACMS, about the FDA approval of adjuvant cemiplimab-rwlc (Libtayo) for the treatment of patients with high-risk cutaneous squamous cell carcinoma (CSCC). Dr Patel is an associate professor of dermatology at the GW School of Medicine & Health Sciences, as well as th…

1
S14 Ep33: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum 32:50

1M ago32:50

32:50

In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.By OncLive® On Air

1
S14 Ep32: Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD 13:26

1M ago13:26

13:26

In today’s episode, we had the pleasure of speaking with Eunice Wang, MD, about the secondary AML treatment paradigm. Dr Wang is a professor of oncology, leader of the Leukemia Clinical Disease Team, chief of leukemia in the Department of Medicine, and an assistant member of the Tumor Immunology Program in the Department of Immunology at Roswell Pa…

1
S14 Ep31: Metastatic Breast Cancer 2025 UPDATE 11:41

2M ago11:41

11:41

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University…

1
S14 Ep30: FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP 4:36

2M ago4:36

4:36

In today’s episode, we had the pleasure of speaking with J. Thaddeus Beck, MD, FACP, about the FDA approval of pembrolizumab and berahyaluronidase alfa-pmph (subcutaneous pembrolizumab; Keytruda Qlex) for subcutaneous injection in adult and pediatric patients at least 12 years of age with solid tumors for which the intravenous formulation of pembro…

1
S14 Ep29: Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD 38:01

2M ago38:01

38:01

Cancer, Character, and Calling: The Oncologist's Journey, hosted by Girindra Raval, MD, is a podcast highlighting how top oncologists have navigated the field over the course of their careers, the passion that drove them to enter the oncology space, and the ongoing work that will continue to transform cancer care. Each episode, Raval will sit down …

1
S14 Ep28: Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress 13:27

2M ago13:27

13:27

In today’s episode, leading experts across oncology specialties previewed the key studies and data they are most anticipating ahead of the 2025 ESMO Congress. Dana M. Chase, MD, a professor of Clinical Obstetrics and Gynecology in the Division of Gynecologic Oncology at UCLA, discussed her excitement to see findings from a phase 1 trial (NCT0540355…

1
S14 Ep27: FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR 11:55

2M ago11:55

11:55

In today’s episode, we had the pleasure of speaking with Joseph Jacob, MD, MCR, about the FDA approval of the gemcitabine intravesical system (formerly TAR-200; Inlexzo) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer. Dr Jacob is an associate professor of urology and the director of Urologic Oncology in the …

1
S14 Ep26: FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD 5:43

2M ago5:43

5:43

In today’s episode, we had the pleasure of speaking with Lyudmila Bazhenova, MD, about the FDA approval of sunvozertinib (Zegfrovy) for patients with EGFR-mutated metastatic non–small cell lung cancer (NSCLC). Dr Bazhenova is a clinical professor of medicine at the University of California San Diego (UCSD); as well as a medical oncologist at the UC…

1
S14 Ep25: Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD 9:26

2M ago9:26

9:26

By OncLive® On Air

1
S14 Ep24: FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD 12:45

2M ago12:45

12:45

In today’s episode, we had the pleasure of speaking with Anne Chiang, MD, PhD, and Stephen Liu, MD, about the FDA approval of lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose diseas…

1
S14 Ep23: Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD 9:48

2M ago9:48

9:48

In today’s episode, we had the pleasure of speaking with Stephen Liu, MD, about the use of tepotinib (Tepmetko) in patients with metastatic non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Dev…

1
S14 Ep22: Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD 11:11

2M ago11:11

11:11

In today’s episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida. In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with m…

1
S14 Ep21: Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD 8:48

2M ago8:48

8:48

In our exclusive interview, Dr Shitara discussed preliminary efficacy data with CAR T-cell therapy in gastrointestinal cancers; highlighted challenges related to durability of response, patient selection, and manufacturing logistics with these therapies; and outlined ongoing biomarker analyses exploring tumor microenvironment factors influencing re…

1
S14 Ep20: The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD 16:19

2M ago16:19

16:19

In today’s episode, we had the pleasure of speaking with Asad Dean, MD, about treatment selection for patients with chronic lymphocytic leukemia (CLL) in the second-line setting. Dr Dean is a physician at the Texas Oncology-Fort Worth Cancer Center. In our exclusive interview, Dr Dean discussed the roles of covalent BTK inhibitors and BCL-2 inhibit…

1
S14 Ep19: Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD 8:28

3M ago8:28

8:28

In today’s episode, we had the pleasure of speaking with Alexander Drilon, MD, about the phase 1/2 ARROS-1 trial (NCT05118789) investigating zidesamtinib (NVL-520) in TKI-pretreated patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Dr Drilon is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Cen…

1
S14 Ep18: Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD 16:13

3M ago16:13

16:13

In our exclusive interview, Dr Chase discussed the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies. For first recurrences, she explained that carboplatin and paclitaxel with pembrolizumab (Keytruda) or dostarlimab-gxly (Jemperli) is recommended for patients with mismatch repair–def…

1
S14 Ep17: Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC 18:28

3M ago18:28

18:28

In this podcast, experts Aditya Bardia, MD, MPH, FASCO, Erika P. Hamilton, MD, and Virginia Kaklamani, MD, DSc, discuss frequently asked questions regarding the use of antibody-drug conjugates (ADCs) in triple-negative breast cancer (TNBC).By OncLive® On Air

1
S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC 18:30

3M ago18:30

18:30

In this podcast, experts Virginia Kaklamani, MD, DSc, and Tiffany A. Traina, MD, FASCO, discuss the rationale for and data to support combining TROP2-targeting antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) to treat triple-negative breast cancer (TNBC).By OncLive® On Air

1
S14 Ep15: Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD 7:02

3M ago7:02

7:02

In today’s episode, we had the pleasure of speaking with Evelyn Y. Wong, MD, about the growing challenge of early-onset colorectal cancer (CRC) and the insights from a recent cohort analysis conducted in Singapore. Dr Wong is a consultant medical oncologist specializing in gastrointestinal cancers at the National Cancer Centre Singapore. In our exc…

1
S14 Ep14: Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC 18:17

3M ago18:17

18:17

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; and Tiffany A. Traina, MD, FASCO; discuss navigating between currently available therapies for patients with triple-negative breast cancer (TNBC). They also discuss the potential ramifications of ongoing clinical trials on future treatment paradigms.…

1
S14 Ep13: Dissecting Clinical Trial and Real-World Data for ADCs in TNBC 20:08

3M ago20:08

20:08

In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss recent clinical trial and real-world data for antibody-drug conjugates (ADCs) used to treat triple-negative breast cancer (TNBC).By OncLive® On Air